Revenue: As of FY2025 Q3, the actual value is USD 47.96 M, beating the estimate of USD 47.76 M.EPS: As of FY2025 Q3, the actual value is USD 0.22, beating the estimate of USD 0.0467.EBIT: As of FY2025 Q3, the actual value is USD 11 M.<h3>Segment Revenue</h3><ul><li>Product Revenue: $46,953 thousand for the three months ended September 30, 2025, compared to $49,806 thousand for the same period in 2024. For the nine months ended September 30, 2025, product revenue was $141,635 thousand compared to $143,952 thousand in 2024.</li><li>Service Revenue: $1,003 thousand for the three months ended September 30, 2025, compared to $1,578 thousand for the same period in 2024. For the nine months ended September 30, 2025, service revenue was $4,176 thousand compared to $3,405 thousand in 2024.</li></ul><h3>Operational Metrics</h3><ul><li>Net Income: $9,216 thousand for the three months ended September 30, 2025, compared to $12,657 thousand for the same period in 2024. For the nine months ended September 30, 2025, net income was $28,980 thousand compared to a net loss of - $3,437 thousand in 2024.</li><li>Cost of Revenue: $13,538 thousand for the three months ended September 30, 2025, compared to $15,278 thousand for the same period in 2024. For the nine months ended September 30, 2025, cost of revenue was $40,023 thousand compared to $44,091 thousand in 2024.</li><li>Selling, General and Administrative Expense: $26,151 thousand for the three months ended September 30, 2025, compared to $23,922 thousand for the same period in 2024. For the nine months ended September 30, 2025, selling, general and administrative expense was $77,066 thousand compared to $74,422 thousand in 2024.</li></ul><h3>Cash Flow</h3><ul><li>Net Cash Provided by Operating Activities: $27,625 thousand for the nine months ended September 30, 2025, compared to $32,875 thousand for the same period in 2024.</li><li>Net Cash Used in Investing Activities: - $4,500 thousand for the nine months ended September 30, 2025, compared to - $17,487 thousand for the same period in 2024.</li><li>Net Cash Used in Financing Activities: - $34,424 thousand for the nine months ended September 30, 2025, compared to - $66,149 thousand for the same period in 2024.</li></ul><h3>Unique Metrics</h3><ul><li>Adjusted EBITDA: $12,881 thousand for the three months ended September 30, 2025, compared to $16,202 thousand for the same period in 2024. For the nine months ended September 30, 2025, Adjusted EBITDA was $41,807 thousand compared to $43,102 thousand in 2024.</li></ul><h3>Future Outlook and Strategy</h3><ul><li>Core Business Focus: The company aims to increase the number of Biote-certified practitioners, grow the practice of Biote-certified practitioners and Biote-partnered clinics, and increase sales of Biote-branded dietary supplements.</li><li>Non-Core Business: The company is focused on vertical integration through strategic transactions, such as the acquisition of Asteria Health, to strengthen control over its supply chain, enhance operational efficiency, and reduce production costs.</li><li>Priority: The company plans to continue meeting product demands of current Biote-practitioners while expanding its Biote-certified clinic network.</li></ul>

biote Corp. | 10-Q: FY2025 Q3 Revenue Beats Estimate at USD 47.96 M